###begin article-title 0
Divergent Cardiopulmonary Actions of Heme Oxygenase Enzymatic Products in Chronic Hypoxia
###end article-title 0
###begin p 1
Performed the experiments: SV. Wrote the paper: SV. PI of laboratory, provided overall scientific direction and funded the research: SK. Edited the manuscript: SK SAM HC. Performed all animal experiments, cardiomyocyte work, proliferation studies: SV. Provided intellectual input, maintained HO-1 null line, engineered hypoxia chamber setup and software control, and taught several animal techniques to Dr. Vitali: SAM. Performed right ventricular pressure measurements for several experiments: ODL XL. Taught Dr. Vitali histological techniques and lung inflation: AFG. Analyzed pulmonary arteriolar remodeling: HC. Performed smooth muscle cell migration experiments: XW. Cardiac anesthesiologist who directed cardiomyocyte experiments: FXM.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 125 128 125 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 409 412 409 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 129 133 <span type="species:ncbi:10090">mice</span>
###xml 413 417 <span type="species:ncbi:10090">mice</span>
Hypoxia and pressure-overload induce heme oxygenase-1 (HO-1) in cardiomyocytes and vascular smooth muscle cells (VSMCs). HO-1-/- mice exposed to chronic hypoxia develop pulmonary arterial hypertension (PAH) with exaggerated right ventricular (RV) injury consisting of dilation, fibrosis, and mural thrombi. Our objective was to indentify the HO-1 product(s) mediating RV protection from hypoxic injury in HO-1-/- mice.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 4 7 4 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 226 229 226 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 403 406 403 406 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 481 484 481 484 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 542 550 542 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 8 12 <span type="species:ncbi:10090">mice</span>
###xml 242 246 <span type="species:ncbi:10090">mice</span>
###xml 407 411 <span type="species:ncbi:10090">mice</span>
###xml 485 489 <span type="species:ncbi:10090">mice</span>
HO-1-/- mice were exposed to seven weeks of hypoxia and treated with inhaled CO or biliverdin injections. CO reduced right ventricular systolic pressure (RVSP) and prevented hypoxic pulmonary arteriolar remodeling in both HO-1-/- and control mice. Biliverdin had no significant effect on arteriolar remodeling or RVSP in either genotype. Despite this, biliverdin prevented RV failure in the hypoxic HO-1-/- mice (0/14 manifested RV wall fibrosis or thrombus), while CO-treated HO-1-/- mice developed RV insults similar to untreated controls. In vitro, CO inhibited hypoxic VSMC proliferation and migration but did not prevent cardiomyocyte death from anoxia-reoxygenation (A-R). In contrast, bilirubin limited A-R-induced cardiomyocyte death but did not inhibit VSMC proliferation and migration.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
CO and bilirubin have distinct protective actions in the heart and pulmonary vasculature during chronic hypoxia. Moreover, reducing pulmonary vascular resistance may not prevent RV injury in hypoxia-induced PAH; supporting RV adaptation to hypoxia and preventing RV failure must be a therapeutic goal.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 636 639 636 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Duckers1">[1]</xref>
###xml 641 644 641 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Zhang1">[2]</xref>
###xml 674 677 674 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Foo1">[3]</xref>
###xml 709 712 709 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Hu1">[4]</xref>
###xml 714 717 714 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Tongers1">[5]</xref>
###xml 760 763 760 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Yet1">[6]</xref>
###xml 764 767 764 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Foresti1">[8]</xref>
###xml 784 792 784 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 797 804 797 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Chronic hypoxia causes remodeling of the pulmonary vasculature with increased proliferation and migration of vascular smooth muscle cells (VSMC), increased pulmonary vascular resistance, increased pulmonary artery pressure, and right ventricular hypertrophy. This clinical condition of "pulmonary hypertension" ultimately leads to death as the right ventricular hypertrophy progresses to dilation and failure. Heme oxygenase-1 (HO-1), an inducible enzyme which degrades the oxidant heme to produce equimolar products of carbon monoxide (CO), biliverdin, and ferrous iron, has been reported to protect animals from proliferation of VSMC [1], [2], apoptosis of cardiomyocytes [3], hypertrophy of cardiomyocytes [4], [5], and cardiac ischemia -reperfusion injury [6]-[8] in a variety of in vitro and in vivo studies.
###end p 9
###begin p 10
###xml 73 76 73 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Morita1">[9]</xref>
###xml 78 82 78 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Kacimi1">[10]</xref>
###xml 110 114 110 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Wagner1">[11]</xref>
###xml 188 192 188 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Katayose1">[12]</xref>
###xml 231 234 231 234 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 515 519 515 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Yet2">[13]</xref>
###xml 738 742 738 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Minamino1">[14]</xref>
###xml 855 858 855 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Yet1">[6]</xref>
###xml 235 239 <span type="species:ncbi:10090">mice</span>
###xml 350 354 <span type="species:ncbi:10090">mice</span>
HO-1 is known to be potently induced in VSMC under conditions of hypoxia [9], [10] and increased shear stress [11], and in cardiomyocytes under conditions of hypoxia and pressure overload [12]. We have previously reported that HO-1-/- mice exposed to seven weeks of chronic hypoxia develop pulmonary vascular remodeling which is similar to wild-type mice, but their right ventricle (RV) develops a more severe injury pattern characterized by areas of wall fibrosis, apoptosis, lipid peroxidation, and mural thrombi [13]. Although the lack of HO-1 is not associated with worsened pulmonary vascular remodeling in response to hypoxia, constitutive overexpression of HO-1 by type II pneumocytes reduces hypoxic pulmonary vascular remodeling [14]. In the heart, cardiac-specific overexpression of HO-1 protects the myocardium from ischemia-reperfusion injury [6]. Taken together, these data suggest that HO-1 and its enzymatic products provide protection of both the myocardium and the lung vasculature under conditions of hypoxia.
###end p 10
###begin p 11
###xml 290 294 290 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Motterlini1">[15]</xref>
###xml 296 300 296 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Brune1">[16]</xref>
###xml 374 378 374 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Morita2">[17]</xref>
###xml 379 383 379 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Zhen1">[20]</xref>
###xml 510 514 510 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Otterbein1">[21]</xref>
###xml 547 551 547 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Dolinay1">[22]</xref>
###xml 578 582 578 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Sato1">[23]</xref>
###xml 790 794 790 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Zuckerbraun1">[24]</xref>
###xml 944 948 944 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Guo1">[25]</xref>
###xml 950 954 950 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Stein1">[26]</xref>
###xml 776 780 <span type="species:ncbi:10090">mice</span>
###xml 785 789 <span type="species:ncbi:10116">rats</span>
###xml 891 896 <span type="species:ncbi:10090">mouse</span>
###xml 901 904 <span type="species:ncbi:10116">rat</span>
The protective effects of HO-1 are likely the result of the action of its enzymatic products, CO and biliverdin, which is converted by biliverdin reductase to bilirubin. CO activates guanylyl cyclase to produce cGMP, a vasorelaxant second messenger molecule with anti-thrombotic properties [15], [16]. CO also has anti-inflammatory actions and is anti-proliferative in VSMC [17]-[20]. Inhaled CO has been shown to be protective in animal models of inflammatory conditions such as sepsis, hyperoxic lung injury [21], ventilator-induced lung injury [22], and transplant rejection [23]. More recently, Zuckerbraun, et al. have reported that intermittently inhaled CO reverses pulmonary hypertension in different animal models, including hypoxia-induced pulmonary hypertension in mice and rats [24]. In the heart, CO delivered by a CO releasing molecule has been shown to reduce infarct size in mouse and rat models of cardiac ischemia-reperfusion [25], [26].
###end p 11
###begin p 12
###xml 321 325 321 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Stocker1">[27]</xref>
###xml 326 330 326 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Nakao1">[30]</xref>
###xml 412 419 412 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 419 423 419 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Yamashita1">[31]</xref>
###xml 499 503 499 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Yamashita1">[31]</xref>
###xml 529 533 529 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Ollinger1">[32]</xref>
###xml 572 576 572 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-SaradyAndrews1">[33]</xref>
###xml 743 747 743 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Clark1">[34]</xref>
###xml 727 730 <span type="species:ncbi:10116">rat</span>
Increasing evidence suggests that bilirubin and biliverdin may have protective effects that rival those of the better-studied HO-1 product, CO. Biliverdin and bilirubin are potent antioxidants that have anti-inflammatory properties and also reduce vascular intimal growth and wound migration in models of vascular injury [27]-[30]. Injected biliverdin hydrochloride (BV), which is rapidly converted to bilirubin in vivo[31], has been shown to be protective in models of cardiac transplant rejection [31], vascular intimal injury [32], and sepsis-induced acute lung injury [33]. In the heart, bilirubin ameliorated postischemic myocardial dysfunction and infarct size in response to ischemia-reperfusion in an isolated-perfused rat heart model [34].
###end p 12
###begin p 13
###xml 348 351 348 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 512 515 512 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 352 357 <span type="species:ncbi:10090">mouse</span>
###xml 516 520 <span type="species:ncbi:10090">mice</span>
Since HO-1 deficiency results in the characteristic pattern of right heart fibrotic injury with overlying mural thrombus and failure in response to chronic hypoxia, we sought to identify the enzymatic product of HO-1 that is critical for cardioprotection under hypoxia. The main findings of our study are that biliverdin treatment protects the HO-1-/- mouse from RV injury and an exaggerated increase in RV weight after seven weeks of chronic hypoxia without diminishing pulmonary hypertension. In contrast, HO-1-/- mice treated with inhaled CO are protected from pulmonary vascular remodeling, however, they still develop RV failure and thrombus with significant mortality, despite normal right ventricular pressures. The divergent effects of two enzymatic products of HO-1 in the same disease model highlight the complexity of HO-1's protective actions in the cardiovascular system. Moreover, the finding that CO protected from pulmonary hypertension but failed to protect from RV injury indicates that hypoxia has a direct effect on the right ventricle that is not mediated by pulmonary vascular constriction or remodeling.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
Animal Model and Hypoxia Exposure
###end title 15
###begin p 16
###xml 4 7 4 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 44 48 44 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Yet2">[13]</xref>
###xml 68 71 68 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 142 145 142 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 8 12 <span type="species:ncbi:10090">mice</span>
###xml 93 97 <span type="species:ncbi:10090">mice</span>
###xml 146 150 <span type="species:ncbi:10090">mice</span>
###xml 238 246 <span type="species:ncbi:9606">Children</span>
HO-1-/- mice have been previously described [13]. Controls were HO-1+/- littermates as these mice do not develop the RV pathology seen in HO-1-/- mice after 7 weeks of hypoxia (data not shown). All animal experiments were approved by the Children's Hospital Animal Care and Use Committee.
###end p 16
###begin p 17
###xml 76 77 76 77 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 242 243 242 243 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice between 8-12 weeks of age were exposed to normobaric hypoxia at 8-10% O2 with or without 20-60 ppm CO in a plexiglass chamber where gas delivery is controlled by an OxyCycler (BioSpherix, Redfield, NY). Ventilation is adjusted so that CO2 does not exceed 5,000 ppm (0.5%) and ammonia is removed with charcoal filtration. Animals were pretreated with either inhaled CO (20-60 ppm) or biliverdin IX hydrochloride (Frontier Scientific, Logan, UT) (50 micromol/kg ip) one hour prior to the experiment and them maintained in continuous CO or daily BV (or PBS vehicle) injection. CO-oximetry was performed weekly using sentinel animals. Cages were changed and food and water replenished weekly for all animals.
###end p 17
###begin title 18
RVSP Measurements
###end title 18
###begin p 19
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice were anesthetized with pentobarbital (60 mg/kg) and remained spontaneously breathing. A transverse incision was made in the abdominal wall, a 23-gauge needle with tubing attached to a pressure transducer was inserted through the diaphragm into the RV, and pressure was recorded with PowerLab monitoring hardware and software (ADInstruments, Colorado Springs, CO). Animals with heart rates less than 300 BPM were excluded. Mean RVSP over the first ten stable heartbeats was recorded.
###end p 19
###begin title 20
Histological Analysis and RV Weight Measurements
###end title 20
###begin p 21
###xml 144 145 144 145 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice were anesthetized as described above and perfused through the RV with PBS. After inflation of the lungs under constant pressure (15-20 cm H2O) with 4% paraformaldehyde (PFA), lungs and hearts were removed and postfixed in PFA overnight. Tissues were paraffin-embedded and 5 microm thick sections obtained for histological analysis. For RV weight measurements, hearts were removed before fixation and both ventricles and LV+septum weighed. Heart weight was normalized for animal weight differences.
###end p 21
###begin p 22
###xml 272 275 268 271 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ext</sub>
###xml 282 285 278 281 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">int</sub>
###xml 290 293 286 289 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ext</sub>
###xml 309 312 305 308 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ext</sub>
###xml 321 324 317 320 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">int</sub>
For pulmonary histology, H&E stained sections were analyzed and 50-100 microm arterioles were captured with a microscope digital camera system (DXM1200F, Nikon, Japan), and areas obtained using computer-based analysis (NIH Image 1.55). Percentage wall thickness (%) = areaext - areaint/areaext x100 where areaext and areaint are the area bounded by external and internal elastic lamina, respectively.
###end p 22
###begin p 23
###xml 236 243 236 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
For cardiac histology, sections were stained with H&E and Masson's trichrome to determine RV fibrosis or analyzed with terminal deoxynucleotide transferase-mediated dUTP nick end-labeling (TUNEL) to detect DNA breaks in apoptotic cells in situ. Hearts were considered positive for RV fibrosis if they contained an area staining positive for Masson's trichrome which extended from the inner aspect to the outer aspect of the RV free wall.
###end p 23
###begin title 24
Cardiomyocyte (CM) Isolation and Anoxia-Reoxygenation (A-R) Exposure
###end title 24
###begin p 25
###xml 390 391 390 391 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 773 774 773 774 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 781 782 781 782 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 793 794 793 794 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 54 65 <span type="species:ncbi:10116">Wistar rats</span>
Neonatal ventricular CMs were isolated from 1 day-old Wistar rats and cultured using a commercially available system (Cellutron, Highland Park NJ). Contaminating cardiac fibroblasts were removed by pre-plating cells for 2 hours in uncoated culture flasks. CMs were plated at a density of 25,000 cells/well in 96-well plates. After 48 hours of culture, media were changed in a hypoxic (<1% O2) workstation (Ruskinn Technologies, Ltd., Bridgeend, UK) to glucose-free substrate deprivation media pre-equilibrated in hypoxia for 18 hours. CMs were treated with bilirubin HCl (Sigma-Aldrich St. Louis, MO) in PBS or the CO-releasing molecule tricarbonyldichlororuthenium (II) dimer (CORM-1) (Sigma-Aldrich, St. Louis MO) in DMSO or with vehicle control. CO gas at 250 ppm (21% O2, 5% CO2, balance N2) was also used to treat CMs on a separate plate for one hour prior to A-R using Billups chambers (Billups-Rothenberg, Inc., Del Mar, CA). Conditions were replicated in 4-6 wells per plate. Plates were placed in anoxic bags (BD Biosciences, Sparks MD) or left normoxic (controls) and cultured at 37degrees C for 6 hours. Media were changed to normoxic glucose-containing media with the same concentrations of BR, CORM I, or vehicle and incubated at 37degrees C for an additional 42 hours.
###end p 25
###begin title 26
Cardiomyocyte Cell Viability/Death Assay
###end title 26
###begin p 27
Calcein and ethidium staining was performed using a commercially available viability/cytotoxicity assay (Molecular Probes, Eugene OR). Plates were read on a Packard Fusion fluorescence platereader (Perkin Elmer, Wellesley MA). Calcein to ethidium fluorescence ratio was calculated for each well. Lactate Dehydrogenase (LDH) was also measured using a commercially available kit (Sigma, St.Louis).
###end p 27
###begin title 28
Cardiomyocyte Apoptosis Assay
###end title 28
###begin p 29
CMs were exposed to A-R as described above except that reoxygenation was 20 hours. CMs were collected and stained for phosphatidylserine (PS) using FITC-labeled Annexin V. Disruption of CM membranes was detected using 7-alpha actinomycin D (7AAD) (Invitrogen, Carlsbad, CA). Labeling was assessed with a Dako Cytomation MoFlo flow cytometer (Dako, Glostrup, Denmark). Quadrants were defined using unstained and single-stained cell populations. CMs staining positive for PS but negative for 7-AAD were counted and presented as a proportion of all CMs in the sample.
###end p 29
###begin title 30
PASMC Proliferation
###end title 30
###begin p 31
###xml 192 193 192 193 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 314 315 310 311 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 0 3 <span type="species:ncbi:10116">Rat</span>
Rat PASMC (passage<15) were plated on 96-well plates and serum-deprived for 72 hours. Platelet-derived growth factor (PDGF) stimulated (25 ng/mL)- or unstimulated controls were exposed to 1% O2 in a hypoxia workstation in the presence or absence of 1 or 5 microM BR or PBS vehicle. Other cells were exposed to 1% O2 and 250 ppm CO inside an airtight Billups chamber. Hypoxic media from the workstation and the Billups chambers were analyzed for pO2 levels using a blood gas analyzer and were found to range between 14 and 25 mmHg in both chambers. After 21 hours, BrdU was added for the final 3 hours of incubation. BrdU incorporation was assessed using a commercially available ELISA (Roche Diagnostics, Mannheim, Germany).
###end p 31
###begin title 32
PASMC Migration
###end title 32
###begin p 33
###xml 596 599 582 585 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">410</sub>
PASMCs were incubated as above in normoxia or 1% hypoxia with or without 250 ppm CO or 5 microM BR for 18 hours before counting and plating in triplicate on the inserts of an 8 microm pore Costar Transwell Plate (Corning, Inc., Corning, NY). PDGF (50 ng/mL) was added to the lower chamber. After 6 hours, an acid phosphatase assay for cell number was performed by incubating the transmigrated cells in substrate solution (10 mM P-nitrophenol phosphate (Sigma), 10 mM sodium acetate, 0.1% Triton X-100, pH 5.8) for 1.5 h at 37degreesC. After addition of 0.05 ml 1 N NaOH to quench the reaction, OD410 was measured using a microplate reader.
###end p 33
###begin title 34
Statistics
###end title 34
###begin p 35
Graphs and statistics were performed using the GraphPad Prism 4 software and (GraphPad, San Diego, CA). Significance of differences was assessed non-parametrically using Mann-Whitney U test.
###end p 35
###begin title 36
Results
###end title 36
###begin title 37
Inhaled CO but not biliverdin inhibits pulmonary hypertension
###end title 37
###begin p 38
###xml 255 258 255 258 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 267 270 267 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 325 328 325 328 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 371 374 371 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 500 504 500 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Yet2">[13]</xref>
###xml 614 617 614 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 626 629 626 629 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 912 915 912 915 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 923 926 923 926 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 1116 1124 1116 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005978-g001">Figure 1</xref>
###xml 157 161 <span type="species:ncbi:10090">mice</span>
###xml 329 333 <span type="species:ncbi:10090">mice</span>
###xml 375 379 <span type="species:ncbi:10090">mice</span>
###xml 1110 1114 <span type="species:ncbi:10090">mice</span>
To assess the impact of inhaled CO and biliverdin injections on the development of pulmonary hypertension, we first measured RVSP in spontaneously breathing mice after 7 weeks of chronic hypoxia. Hypoxia caused a significant increase in RVSP for both HO-1-/- and HO-1+/- control animals, as expected. We were able to use HO-1+/- mice as littermate controls since the HO-1+/- mice manifest the same degree of pulmonary hypertension as wild-type and none develop RV fibrosis or thrombus under hypoxia ([13], and results not shown). Continuously inhaled CO inhibited elevation of RVSP in chronic hypoxia for both HO-1-/- and HO-1+/- animals. For both genotypes, CO treatment resulted in significantly lower RVSP values compared with untreated hypoxic animals and with no significant difference from the values obtained in normoxic control animals. Biliverdin injections did not prevent elevated RVSP for either HO-1-/- or HO-1+/- control animals, as biliverdin-treated animals of both genotypes had RVSP which was significantly higher than normoxic controls but not significantly different from untreated hypoxic mice (Figure 1).
###end p 38
###begin title 39
###xml 75 78 75 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 87 90 87 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
Right ventricular systolic pressure (RVSP) after 7 weeks of hypoxia in HO-1-/- and HO-1+/- control mice.
###end title 39
###begin p 40
###xml 12 15 12 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
Mean values +/- SEM are indicated with each dot representing RVSP measurement for one animal. n.s. = not significant, * = p<0.05, *** = p<0.005 as assessed by Mann-Whitney U test.
###end p 40
###begin p 41
###xml 100 103 100 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 112 115 112 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 223 226 223 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 235 238 235 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 343 351 343 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005978-g002">Figure 2</xref>
###xml 383 386 383 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 395 398 395 398 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 239 243 <span type="species:ncbi:10090">mice</span>
Exposure to chronic hypoxia caused significant pulmonary arteriolar wall remodeling in both the HO-1-/- and HO-1+/- animals. Treatment with continuous inhaled CO for 7 weeks prevented arteriolar wall thickening in both HO-1-/- and HO-1+/- mice, while biliverdin injections had no effect on pulmonary arteriolar remodeling for either genotype (Figure 2). In follow-up experiments HO-1-/- and HO-1+/- animals were treated with intermittent inhaled CO at 250 ppm for one hour per day throughout a seven-week hypoxic exposure. Intermittent CO was equally efficacious as continuous CO in preventing arteriolar remodeling and elevated RVSP during chronic hypoxia (data not shown).
###end p 41
###begin title 42
###xml 39 42 39 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
Pulmonary arteriolar remodeling in HO-1-/- animals exposed to chronic hypoxia for seven weeks and treated with CO or Biliverdin, as indicated.
###end title 42
###begin p 43
###xml 67 70 67 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 248 251 248 251 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 252 256 <span type="species:ncbi:10090">mice</span>
(A) Quantification of percent wall thickness. Bars represent means +/- SEM. Each dot represents one animal and ten vessels were averaged for each animal. * = p<0.05 as assessed by Mann-Whitney U test. (B) Representative pulmonary arterioles of HO-1-/- mice stained with H&E for each of the different conditions and treatments above.
###end p 43
###begin title 44
###xml 65 68 65 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 69 73 <span type="species:ncbi:10090">mice</span>
Biliverdin but not inhaled CO prevents RV fibrotic injury in HO-1-/- mice exposed to chronic hypoxia
###end title 44
###begin p 45
###xml 98 101 98 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 201 204 201 204 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 308 311 308 311 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 329 337 329 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005978-g003">Figure 3</xref>
###xml 440 443 436 439 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 501 504 497 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 645 648 641 644 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 715 718 711 714 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 736 744 732 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005978-g003">Figure 3</xref>
###xml 102 106 <span type="species:ncbi:10090">mice</span>
###xml 205 209 <span type="species:ncbi:10090">mice</span>
###xml 444 448 <span type="species:ncbi:10090">mice</span>
To assess the impact of inhaled CO and injected biliverdin on the development of RV injury in HO-1-/- mice, we weighed hearts and evaluated them grossly and histologically. Hypoxic exposure caused HO-1-/- mice to have a more profound elevation in RV weight (normalized to animal weight) as compared with HO-1+/- control animals (Figure 3). Daily injections of biliverdin (50 micromol/kg) prevented the exaggerated RV weight gain in the HO-1-/- mice, while having no effect on the RV weight of the HO-1+/- control animals. Treatment with continuous inhaled CO throughout the hypoxic exposure did not prevent the elevation in RV weight in the HO-1-/- animals and had no significant effect on the RV weight of the HO-1+/- control animals (Figure 3).
###end p 45
###begin title 46
###xml 32 35 32 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 44 47 44 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 56 60 <span type="species:ncbi:10090">mice</span>
Right ventricular weight in HO-1-/- and HO-1+/- control mice after 7 weeks of hypoxia.
###end title 46
###begin p 47
###xml 45 48 45 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
RV weight is indexed to animal weight. Means +/- SEM are shown for the number of animals listed below each column. n.s. = not significant, *** = p<0.005 as assessed by Mann-Whitney U test. N = normoxia, H = hypoxia.
###end p 47
###begin p 48
###xml 31 35 31 35 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Yet2">[13]</xref>
###xml 53 56 53 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 215 234 215 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005978-g004">Figure 4A, B, and C</xref>
###xml 271 274 271 274 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 445 448 445 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 586 595 586 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005978-g004">Figure 4H</xref>
###xml 661 664 661 664 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 763 778 763 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005978-g004">Figure 4A and H</xref>
###xml 873 876 873 876 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 886 898 886 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005978-g004">Figure 4D, E</xref>
###xml 919 922 919 922 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 966 975 966 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005978-g004">Figure 4H</xref>
###xml 1101 1110 1101 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005978-g004">Figure 4F</xref>
###xml 1202 1211 1202 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005978-g004">Figure 4G</xref>
###xml 1221 1224 1221 1224 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 1341 1344 1341 1344 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1484 1487 1484 1487 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1539 1542 1539 1542 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 57 61 <span type="species:ncbi:10090">mice</span>
###xml 275 279 <span type="species:ncbi:10090">mice</span>
###xml 1345 1349 <span type="species:ncbi:10090">mice</span>
As we have previously reported [13], exposure of HO-1-/- mice to chronic hypoxia for seven weeks caused areas of full-thickness RV wall fibrosis, with the majority of the animals having an overlying mural thrombus (Figure 4A, B, and C). RV injury was evident in many HO-1-/- mice on gross examination, with white thrombus protruding from the RV once atria were removed and often visible through a translucent, dilated RV. 45.4% of untreated HO-1-/- animals developed an area of full-thickness right ventricular wall fibrosis as detected with Masson's Trichrome stain after seven weeks (Figure 4H). Biliverdin injections entirely prevented this response; no HO-1-/- animals treated with biliverdin injections had full-thickness RV wall fibrosis after seven weeks (Figure 4A and H). Unlike biliverdin, continuous CO administration did not prevent RV wall fibrosis in the HO-1-/- animals (Figure 4D, E), with 64.3% of HO-1-/- animals treated with CO developing injury (Figure 4H). These areas of fibrotic injury in the untreated and CO-treated animals had many TUNEL-positive apoptotic cells throughout (Figure 4F), while left ventricular cardiomyocytes on the same slide are negative for TUNEL staining (Figure 4G). No HO-1+/- control animals developed RV wall fibrosis or TUNEL-positive areas. In follow up experiments we have found that HO-1-/- mice treated with intermittent inhaled CO (250 ppm CO for one hour a day) developed RV wall fibrosis and thrombus at a rate similar to HO-1-/- animals treated with continuous CO and hypoxic HO-1-/- controls (data not shown).
###end p 48
###begin title 49
###xml 37 40 37 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 41 45 <span type="species:ncbi:10090">mice</span>
Right ventricular wall injury in HO-1-/- mice exposed to chronic hypoxia for seven weeks.
###end title 49
###begin p 50
###xml 151 154 151 154 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 195 198 195 198 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 228 231 228 231 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 336 339 336 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 480 483 480 483 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 731 734 731 734 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 894 897 894 897 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 199 203 <span type="species:ncbi:10090">mice</span>
###xml 232 236 <span type="species:ncbi:10090">mice</span>
###xml 340 345 <span type="species:ncbi:10090">mouse</span>
###xml 484 489 <span type="species:ncbi:10090">mouse</span>
###xml 735 740 <span type="species:ncbi:10090">mouse</span>
###xml 1070 1074 <span type="species:ncbi:10090">mice</span>
(A) Biventricular (short-axis) sections of the heart at the papillary muscle level stained with H&E reveal RV dilation and thrombus in the hypoxic HO-1-/- controls and the CO-treated hypoxic HO-1-/- mice but not the hypoxic HO-1-/- mice treated with BV. (B,C) Masson's trichrome stained right ventricular sections from an untreated HO-1-/- mouse at 40x (B) and 100x (C) power. A fibrotic area of RV wall is evident with overlying mural thrombus. (D,E) Carbon monoxide-treated HO-1-/- mouse RVs stained with Masson's trichrome at 100x (D) and 200x (E) power showing an area of RV wall fibrosis and overlying mural thrombus. (F,G) TUNEL-stained RV (F) and LV (G) wall from an area of full-thickness wall fibrosis in an untreated HO-1-/- mouse at 200x magnification. The LV has TUNEL stained luminal debris but is otherwise negative for TUNEL-staining. (H) Quantification of the percentage of HO-1-/- animals in each group developing an area of Masson's trichrome-positive fibrosis spanning the full thickness of the RV wall. (I) Survival curve of HO-1 hemizygous and null mice in 8.5-9% oxygen for seven weeks in response to treatment with CO or Biliverdin.
###end p 50
###begin p 51
###xml 126 129 126 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 156 158 156 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 164 166 164 166 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 222 231 222 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005978-g004">Figure 4I</xref>
###xml 321 324 321 324 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 347 350 347 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 406 409 406 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 432 434 432 434 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
In addition to its impact on RV weight, development of RV injury affected death prior to 7 weeks. Approximately 12-18% of HO-1-/- animals died between the 6th and 7th weeks of hypoxia in the untreated or CO-treated group (Figure 4I). Interestingly, there were no deaths prior to seven weeks in the biliverdin-treated HO-1-/- groups, or in the HO-1+/- controls. Necropsy on the untreated and CO-treated HO-1-/- animals dying in the 6th week showed white thrombus protruding from the RV when the atria were removed.
###end p 51
###begin title 52
CO but not bilirubin inhibits hypoxic PASMC proliferation and migration
###end title 52
###begin p 53
###xml 227 231 227 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Morita2">[17]</xref>
###xml 233 237 233 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Stanford1">[18]</xref>
###xml 239 243 239 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Zhen1">[20]</xref>
###xml 368 376 368 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 764 768 760 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Morita2">[17]</xref>
###xml 1006 1015 1002 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005978-g005">Figure 5A</xref>
###xml 1085 1094 1081 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005978-g005">Figure 5A</xref>
###xml 1308 1317 1304 1313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005978-g005">Figure 5B</xref>
###xml 1509 1518 1501 1510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005978-g005">Figure 5B</xref>
###xml 447 450 <span type="species:ncbi:10116">rat</span>
VSMC exposed to hypoxia have increased proliferation in response to a mitogenic stimulus over normoxic controls, and as we and others have previously reported, treatment of these cells with CO inhibits their proliferation rate [17], [18], [20]. To begin to investigate the differential responses of the pulmonary vasculature to CO and biliverdin, PASMCs were cultured in vitro and evaluated for proliferation and migration under hypoxia. Cultured rat PASMCs were treated with either bilirubin (5 microM) or CO (250 ppm) and cell proliferation was assessed in response to PDGF stimulation. The specific doses of bilirubin and CO were selected based on our findings in the cardiomyocyte anoxia-reoxygenation experiments (see below) and our previously published work [17]. We used bilirubin instead of biliverdin in case biliverdin reductase was absent or inactive in the cultured cells. Bilirubin treatment did not affect PASMC growth under normoxia and modestly reduced hypoxia-induced PASMC proliferation (Figure 5A). CO (250 ppm) significantly reduced PASMC proliferation in hypoxia (Figure 5A). PDGF, in addition to being a mitogen, is also a chemoattractant for VSMCs and enhances their migration. Migration of PASMCs through a porous membrane across a PDGF gradient was significantly induced by hypoxia (Figure 5B). Interestingly, CO treatment concurrent with hypoxia completely inhibited hypoxia-induced PASMC migration, whereas bilirubin treatment (5 microM) had no effect on hypoxia-induced migration (Figure 5B).
###end p 53
###begin title 54
PASMC proliferation and migration in response to hypoxia.
###end title 54
###begin p 55
(A) Effect of bilirubin and CO on PASMC proliferation in response to hypoxia by BrdU incorporation. Average fold change of relative light units over unstimulated (no PDGF) controls from four experiments are shown. (B) Effect of bilirubin and CO on PASMC migration in hypoxia. Average fold change of relative light units over unstimulated (no PDGF) controls from three experiments is shown. * = p,0.05, *** = p<0.005 as assessed by Mann-Whitney U test.
###end p 55
###begin title 56
Bilirubin protects cardiomyocytes from anoxia-reoxygenation injury
###end title 56
###begin p 57
###xml 11 19 11 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 284 293 284 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005978-g006">Figure 6A</xref>
###xml 304 313 304 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005978-g006">Figure 6B</xref>
###xml 325 328 <span type="species:ncbi:10116">rat</span>
We used an in vitro model of A-R to investigate the cytoprotective effects of bilirubin and CO treatment on the cardiomyocyte. Six hours of anoxia followed by reoxygenation results in a significant amount of cell death of cardiomyocytes as assessed by both calcein/ethidium staining (Figure 6A) and LDH (Figure 6B). Neonatal rat cardiomyocytes treated with bilirubin (1-5 microM) demonstrated increased cell survival rate and were better protected against A-R-induced cell death seen in vehicle-treated controls. Higher concentrations of bilirubin (up to 100 microM) were ineffective in protecting the cardiomyocytes, but were not toxic to normoxic control cardiomyocytes (data not shown). Neither CO gas pre-treatment (250 ppm for one hour prior to exposure), nor the CO releasing molecule I (concentrations from 1 to 20 microM) protected cardiomyocytes from cell death (data not shown).
###end p 57
###begin title 58
Bilirubin protects cardiomyocytes from anoxia-reoxygenation (A-R) injury and has an anti-apoptotic effect.
###end title 58
###begin p 59
###xml 111 114 111 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 331 334 331 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
(A) Cell survival ratio relative to untreated normoxic controls as assessed by calcein/ethidium staining. Mean +/- SEM for 6 wells per condition is shown and graph is representative of three independent experiments. (B) Lactate dehydrogenase (LDH) measured by absorbance at 490 in the media of cardiomyocytes exposed to A-R. Means +/- SEM are shown. (C) Flow cytometric analysis of Annexin V-positive, 7AAD-negative cardiomyocytes after A-R. Bars represent the percentage of 10,000 counted cells that fell into this category. Data are an average of three different experiments. * = p<0.05, ** = p<0.01, *** = p<0.005 as assessed by Mann-Whitney U test.
###end p 59
###begin p 60
###xml 502 511 498 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005978-g006">Figure 6C</xref>
Using flow cytometry for annexin V as an early marker of apoptosis, we evaluated the effect of bilirubin on apoptotic cell death from A-R. To stain dead cells and other cells lacking membrane integrity, 7-AAD was used. Apoptotic cells were identified as those cells staining positive for annexin V and negative for 7-AAD. A-R doubled the percentage of apoptotic cardiomyocytes from the normoxic control levels, and both 1 and 5 microM bilirubin significantly reduced the percentage of apoptotic cells (Figure 6C).
###end p 60
###begin title 61
Discussion
###end title 61
###begin p 62
###xml 220 223 220 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 313 316 313 316 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 573 576 573 576 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 703 706 703 706 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 905 913 905 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 918 925 918 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 985 992 985 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 224 229 <span type="species:ncbi:10090">mouse</span>
###xml 577 581 <span type="species:ncbi:10090">mice</span>
###xml 707 711 <span type="species:ncbi:10090">mice</span>
We have used low dose, continuous inhaled CO and injected biliverdin to investigate the role of these enzymatic products in the pathologic RV response resulting from chronic hypoxia and pulmonary hypertension in the HO-1-/- mouse. Inhaled CO prevented pulmonary arteriolar remodeling and reduced RVSP in both HO-1-/- and control animals, while biliverdin had no significant effect on the pulmonary arteriolar response or RV pressure. Although it prevented hypoxia-induced pulmonary hypertension, inhaled CO had no effect on the development of RV fibrotic injury in the HO-1-/- mice exposed to hypoxia for seven weeks. In contrast, biliverdin treatment reversed the exaggerated RV weight response in HO-1-/- mice and completely prevented RV injury at 7 weeks. Given that both molecules have been reported to protect cardiomyocytes and be anti-proliferative for vascular smooth muscle cells in a variety of in vitro and in vivo injury models, this finding of their differing roles in an in vivo model of pulmonary hypertension is intriguing.
###end p 62
###begin p 63
###xml 794 797 794 797 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 532 540 <span type="species:ncbi:9606">patients</span>
Our study is the first to investigate the roles of HO-1 enzymatic products in protection from cardiac injury secondary to chronic hypoxia-induced pulmonary hypertension. Pulmonary hypertension is characterized by pulmonary vascular remodeling that leads to increased pulmonary vascular resistance and elevated pulmonary arterial pressure. Pressure-overload elevates RV wall stress, causing the RV to hypertrophy and ultimately to begin a progression down the end-stage pathway to dilation, fibrosis, apoptosis and failure. Death in patients with pulmonary hypertension is most often a result of right ventricular failure, but mechanisms for progression from RV hypertrophy to failure are poorly understood. The relatively rapid progression to RV dilation, fibrosis, and failure seen in the HO-1-/- exposed to chronic hypoxia makes it an unique tool to understand the roles of HO-1 and its enzymatic products in this injury.
###end p 63
###begin p 64
###xml 160 163 160 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 617 621 617 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Baranano1">[35]</xref>
###xml 869 876 865 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 688 692 <span type="species:ncbi:10090">mice</span>
The most striking finding of our experiments is that biliverdin administration completely prevented the characteristic RV injury and failure pattern in the HO-1-/- animals exposed to chronic hypoxia. Biliverdin-treated animals had no areas of full-thickness RV wall fibrosis and correspondingly no significant TUNEL-positive areas of increased RV wall apoptosis. Biliverdin itself is a potent antioxidant because of its ability to be reduced by biliverdin reductase to bilirubin in most tissues. Bilirubin can then be oxidized back to biliverdin, which can re-enter this antioxidant cycle and continue the protection [35]. We have found that injections of 50 micromol/kg of biliverdin in mice increase serum bilirubin levels from a baseline of 0.25 mg/dL to 6.8 mg/dL within 15 minutes of injection, providing evidence for the rapidity of biliverdin reductase activity in vivo.
###end p 64
###begin p 65
###xml 136 139 136 139 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 433 436 433 436 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 823 827 823 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Hartsfield1">[36]</xref>
###xml 927 930 927 930 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 964 967 964 967 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 1172 1175 1172 1175 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 140 145 <span type="species:ncbi:10090">mouse</span>
###xml 437 441 <span type="species:ncbi:10090">mice</span>
###xml 659 663 <span type="species:ncbi:10116">rats</span>
###xml 931 935 <span type="species:ncbi:10090">mice</span>
###xml 1176 1180 <span type="species:ncbi:10090">mice</span>
In addition to causing the RV wall fibrotic injury, chronic hypoxia and pressure-overload lead to a heavier, more dilated RV in the HO-1-/- mouse as compared with the hemizygous control animals. This increased weight cannot be explained by a more pronounced hypertrophic response to pulmonary hypertension as the ventricles are dilated, fibrotic, and have mural thrombi. Given the premature death in the untreated and CO-treated HO-1-/- mice, we surmise that cardiac function was significantly impaired as well. Similarly, Hartsfield, et al. reported that although inhibition of HO-1 activity with tin protoprorphyrin did not worsen pulmonary hypertension in rats exposed to hypoxia for 5 weeks, the RV did not hypertrophy appropriately but was dilated and had worsened function as compared with untreated hypoxic controls [36]. In our study, biliverdin treatment prevented the exaggerated RV weight gain seen in untreated HO-1-/- mice, restoring RV weight to HO-1+/- control levels but not preventing the hypertrophic response to hypoxia for either genotype. In sum, biliverdin treatment prevented RV fibrosis and exaggerated weight gain and improved survival in the HO-1-/- mice exposed to chronic hypoxia.
###end p 65
###begin p 66
###xml 500 508 500 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 723 731 719 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 821 824 813 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Foresti1">[8]</xref>
###xml 1571 1575 1559 1563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Redout1">[37]</xref>
###xml 1878 1882 1866 1870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Pachori1">[38]</xref>
###xml 1888 1896 1876 1884 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 127 130 <span type="species:ncbi:10116">rat</span>
###xml 1446 1449 <span type="species:ncbi:10116">rat</span>
In order to better understand the mechanism behind the myocardial protective actions of biliverdin injection, we used neonatal rat cardiomyocytes to examine the effects of HO-1 products on cell survival after A-R injury. Cardiomyoctes in culture are quite resilient to the effects of chronic hypoxia, but profound hypoxia or anoxia followed by reoxygenation is known to cause cell death. We therefore chose this model to investigate the potential direct effects of CO and bilirubin on cardiomyocytes in vitro. We found that cardiomyocytes exposed to A-R had significantly improved survival when treated with low doses of bilirubin (1 and 5 microM). Foresti et al. also found that bilirubin protects cardiomyocytes from A-R in vitro, with lower doses of bilirubin (0.5 microM) being protective while higher doses were not [8]. We also investigated whether bilirubin protected from apoptotic cell death and found that 5 microM bilirubin was anti-apoptotic when assessed by flow cytometry for Annexin V. Biliverdin and bilirubin likely protect cardiomyocytes via their antioxidant actions, and given that reactive oxygen species (ROS) are proposed to be mediators of cardiac injury (apoptosis and fibrosis) by pressure-overload, hypoxia, and ischemia-reperfusion, it follows that these molecules could protect the heart simply by their antioxidant properties. Redout and others recently reported that progression from RV hypertrophy to failure in a rat monocrotaline pulmonary hypertension model is associated with increased ROS production by mitochondria and NADPH oxidase [37]. These failing RVs showed evidence of reduced antioxidant capacity and increased oxidative stress. That the antioxidant property of bilirubin is important for cardioprotection is supported by recent data that HO-1 overexpression protected cardiomyocytes from A-R-induced oxidative injury and apoptosis [38]. Our in vitro data support an anti-apoptotic role for bilirubin but do not rule out that other protective mechanisms are occurring as well, and these may be occurring via anti-oxidant or other pathways.
###end p 66
###begin p 67
###xml 299 303 299 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Gautier1">[39]</xref>
###xml 305 309 305 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Dubuis1">[40]</xref>
###xml 701 709 701 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1094 1098 1094 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Morita2">[17]</xref>
###xml 1268 1271 1268 1271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Duckers1">[1]</xref>
###xml 1273 1277 1273 1277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Kim1">[41]</xref>
###xml 1456 1460 1456 1460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Yamboliev1">[42]</xref>
###xml 178 182 <span type="species:ncbi:10090">mice</span>
###xml 255 259 <span type="species:ncbi:10116">rats</span>
###xml 425 429 <span type="species:ncbi:10090">mice</span>
Continuous inhaled CO concurrent with exposure to chronic hypoxia completely prevented hypoxia-induced pulmonary vascular remodeling and elevated RVSP. Similar to our finding in mice, others have reported that continuous CO reverses elevations in RVSP in rats exposed to chronic hypoxia for 21 days [39], [40]. We demonstrate here that continuous CO inhalation prevents pulmonary vascular remodeling and elevation of RVSP in mice by chronic hypoxia, and likely does so, at least in part, by prevention of hypoxia-induced pulmonary arterial smooth muscle cell proliferation and migration. Bilirubin, in contrast, only modestly reduced hypoxia-induced PASMC proliferation and had no effect on migration in vitro. While we have reported the inhibitory effect of CO on VSMC proliferation in the past, to our knowledge this is the first report of the profound anti-migratory action of CO in hypoxic vascular smooth muscle cells. We have previously reported that the antiproliferative effect of CO in hypoxic VSMC is through cGMP-mediated down-regulation of the cell cycle transcription factor E2F-1 [17], while others have implicated cGMP-dependent phosphorylation of p38 MAP kinase, dephosphorylation of ERK MAP kinase, and regulation of p21 to control cell proliferation [1], [41]. Although the mechanism for hypoxia-induced PASMC migration has not been studied, PASMC migration toward PDGF has been reported to be dependent on ERK MAP kinase phosphorylation [42] and therefore it is plausible that CO inhibits migration via dephosphorylation of ERK 1/2.
###end p 67
###begin p 68
###xml 125 128 125 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 137 140 137 140 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 295 298 295 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 609 613 609 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Zuckerbraun1">[24]</xref>
###xml 945 949 945 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Gautier1">[39]</xref>
###xml 963 966 963 966 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1254 1257 1254 1257 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 1392 1395 1392 1395 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 1738 1742 1738 1742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Gautier1">[39]</xref>
###xml 2136 2144 2136 2144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 2395 2399 2395 2399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Clark2">[43]</xref>
###xml 149 153 <span type="species:ncbi:10090">mice</span>
###xml 299 304 <span type="species:ncbi:10090">mouse</span>
###xml 388 392 <span type="species:ncbi:10116">rats</span>
###xml 478 482 <span type="species:ncbi:10116">rats</span>
###xml 639 643 <span type="species:ncbi:10116">rats</span>
###xml 967 972 <span type="species:ncbi:10090">mouse</span>
###xml 1658 1662 <span type="species:ncbi:10116">rats</span>
A key finding of our study is that despite the protection from pulmonary arteriolar remodeling and elevated RVSP seen in HO-1-/- and HO-1+/- control mice treated with inhaled CO, increased RV weight was not prevented in either genotype and RV fibrosis and apoptosis was not prevented in the HO-1-/- mouse. Other authors who have used CO to treat hypoxia-induced pulmonary hypertension in rats have had conflicting results pertaining to RV hypertrophy. Otterbein, et.al. treated rats with 250 ppm CO once daily during the last three weeks of a six week hypoxic exposure and found improvement in Fulton's Index [24]. Gautier, et.al. treated rats with 50 ppm CO continuously during the last week of a three week hypoxic exposure and found that although RVSP was significantly improved, Fulton's Index was not affected and RV function was significantly worsened in the CO-treated group. In addition, RV infarction developed in some of these animals [39]. For the HO-1-/- mouse that cannot respond to hypoxia by increasing CO production, it appears that neither reducing pulmonary vascular resistance (which occurs as a consequence of CO therapy) nor replacement of CO at the cardiomyocyte level is sufficient to prevent RV injury. Interestingly, for the HO-1+/- control animals treated with CO, elevation of RVSP was prevented but the RV hypertrophied to the same extent as untreated hypoxic HO-1+/- controls. One possible explanation for this effect is CO toxicity, but we monitored COHb levels weekly throughout the hypoxic exposure and found levels less than 9% regardless of CO dose within the range of 20-60 ppm. Others have reported similar COHb levels in rats exposed to chronic hypoxia and continuous inhaled CO at 50 ppm for 3 weeks [39]. These levels are lower than those of chronic smokers and are not thought to be toxic. Another possible explanation is that in hypoxia-induced pulmonary hypertension, CO may be preventing the pulmonary vascular smooth muscle cell proliferative and pro-migratory effects of hypoxia but not protecting from the direct effects of hypoxia on the right ventricle. In support of this, we found that in vitro, neither pre-treatment with CO gas nor CORM-1 treatment improved cardiomyocyte cell survival in a model of anoxia-reoxygenation. A previous study by Clark, et.al. showed that CO was protective when delivered using CORM-3 in H9C2 cells exposed to A-R [43]. The use of a different CO-releasing molecule in a transformed cell line (H9C2) in the Clark study may account for the observed difference between their results and ours.
###end p 68
###begin p 69
###xml 116 119 116 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 393 397 393 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Katayose1">[12]</xref>
###xml 399 403 399 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Delcayre1">[44]</xref>
###xml 424 428 424 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005978-Yet2">[13]</xref>
###xml 120 124 <span type="species:ncbi:10090">mice</span>
###xml 570 578 <span type="species:ncbi:9606">patients</span>
###xml 697 705 <span type="species:ncbi:9606">patients</span>
The fact that CO reduced RVSP and pulmonary arteriolar remodeling but did not prevent RV fibrotic injury in the HO-1-/- mice points to a possible direct effect of hypoxia on the RV. When chronic hypoxia is the cause of pulmonary hypertension, the RV is subjected not only to elevated pulmonary vascular resistance from vascular remodeling, but also to systemic hypoxia. Both pressure-overload [12], [44] and chronic hypoxia [13] are known to independently increase HO-1 expression in the heart, pointing to a possible independent role of these two stressful stimuli. As patients with PAH secondary to hypoxia (e.g. secondary to chronic obstructive pulmonary disease) make up a large percentage of patients with PAH, it is important that we investigate this independent effect of systemic hypoxia on myocardial performance and progression to failure.
###end p 69
###begin p 70
###xml 71 74 71 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 280 283 280 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 292 295 292 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 388 391 388 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 75 79 <span type="species:ncbi:10090">mice</span>
###xml 1654 1662 <span type="species:ncbi:9606">patients</span>
In summary, biliverdin exerted a direct cardioprotective effect in HO-1-/- mice exposed to chronic hypoxia, but did not ameliorate pulmonary vascular pathology. In the same model, inhalation of low dose continuous CO ameliorated hypoxia-induced pulmonary hypertension in both HO-1+/- and HO-1-/- animals, but did not protect from RV dilation, fibrosis, and mural thrombus. Given that HO-1-/- animals appear to have an accelerated progression to apoptosis, fibrosis, and heart failure, we propose that biliverdin administration slows this progression to resemble the wild-type phenotype while CO either has no effect or accelerates the progression. At the same time, CO dramatically inhibits hypoxia-induced proliferation and migration of vascular smooth muscle cells and prevents hypoxic pulmonary vascular remodeling and RV pressure overload, but has no protective effects on the RV. The distinctly different roles of these two protective enzymatic products of HO-1 in our model of hypoxia-induced pulmonary hypertension are intriguing and may demonstrate how HO-1 can have a variety of protective effects that are dependent on the type of stress and the type of cell involved in injury. As therapeutic strategies that involve upregulation of HO-1 or delivery of its enzymatic products are developed, there will need to be thorough investigation of the possible effects of these strategies in each organ system. In general, our results support the emerging concept that treatments for pulmonary hypertension targeted solely at reducing pulmonary arterial pressure may not necessarily be cardioprotective and may not ultimately improve outcome for these patients. Potential treatments must be evaluated for their protective actions in both organ systems.
###end p 70
###begin p 71
The authors wish to thank Dimitrios Poutias for his assistance with cardiomyocyte isolation techniques, Hilary Mehler and Xianlan Liu for technical assistance, and Stephanie Giannetto and Sarah Gately for their expert assistance in preparation of the manuscript.
###end p 71
###begin title 72
References
###end title 72
###begin article-title 73
Heme oxygenase-1 protects against vascular constriction and proliferation.
###end article-title 73
###begin article-title 74
Overexpression of heme oxygenase-1 protects smooth muscle cells against oxidative injury and inhibits cell proliferation.
###end article-title 74
###begin article-title 75
###xml 64 67 <span type="species:ncbi:10116">rat</span>
Heme oxygenase-1 gene transfer inhibits angiotensin II-mediated rat cardiac myocyte apoptosis but not hypertrophy.
###end article-title 75
###begin article-title 76
Heme oxygenase-1 inhibits angiotensin II-induced cardiac hypertrophy in vitro and in vivo.
###end article-title 76
###begin article-title 77
Heme oxygenase-1 inhibition of MAP kinases, calcineurin/NFAT signaling, and hypertrophy in cardiac myocytes.
###end article-title 77
###begin article-title 78
###xml 100 115 <span type="species:ncbi:10090">transgenic mice</span>
Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice.
###end article-title 78
###begin article-title 79
###xml 91 95 <span type="species:ncbi:10090">mice</span>
Absence of heme oxygenase-1 exacerbates myocardial ischemia/reperfusion injury in diabetic mice.
###end article-title 79
###begin article-title 80
Role of heme oxygenase-1 in hypoxia-reoxygenation: requirement of substrate heme to promote cardioprotection.
###end article-title 80
###begin article-title 81
Smooth muscle cell-derived carbon monoxide is a regulator of vascular cGMP.
###end article-title 81
###begin article-title 82
Hypoxia differentially regulates stress proteins in cultured cardiomyocytes: Role of the p38 stress-activated signaling cascade, and relation to cytoprotection.
###end article-title 82
###begin article-title 83
Hemodynamic forces induce the expression of heme oxygenase in cultured vascular smooth muscle cells.
###end article-title 83
###begin article-title 84
###xml 87 90 <span type="species:ncbi:10116">rat</span>
Separate regulation of heme oxygenase and heat shock protein 70 mRNA expression in the rat heart by hemodynamic stress.
###end article-title 84
###begin article-title 85
###xml 92 96 <span type="species:ncbi:10090">mice</span>
Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase-1 null mice.
###end article-title 85
###begin article-title 86
Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia.
###end article-title 86
###begin article-title 87
Heme oxygenase-1-derived carbon monoxide contributes to the suppression of acute hypertensive responses in vivo.
###end article-title 87
###begin article-title 88
Inhibition of platelet aggregation by carbon monoxide is mediated by activation of guanylate cyclase.
###end article-title 88
###begin article-title 89
Carbon monoxide controls the proliferation of hypoxic vascular smooth muscle cells.
###end article-title 89
###begin article-title 90
###xml 31 36 <span type="species:ncbi:9606">human</span>
Heme oxygenase is expressed in human pulmonary artery smooth muscle where carbon monoxide has an anti-proliferative role.
###end article-title 90
###begin article-title 91
Heme oxygenase-1-derived carbon monoxide is an autocrine inhibitor of vascular smooth muscle cell growth.
###end article-title 91
###begin article-title 92
Carbon monoxide inhibits proliferation of pulmonary smooth muscle cells under hypoxia.
###end article-title 92
###begin article-title 93
Carbon monoxide provides protection against hyperoxic lung injury.
###end article-title 93
###begin article-title 94
Inhaled carbon monoxide confers antiinflammatory effects against ventilator-induced lung injury.
###end article-title 94
###begin article-title 95
###xml 74 79 <span type="species:ncbi:10090">mouse</span>
###xml 83 86 <span type="species:ncbi:10116">rat</span>
Carbon monoxide generated by heme oxygenase-1 suppresses the rejection of mouse-to-rat cardiac transplants.
###end article-title 95
###begin article-title 96
Carbon monoxide reverses established pulmonary hypertension.
###end article-title 96
###begin article-title 97
Administration of a CO-releasing molecule at the time of reperfusion reduces infarct size in vivo.
###end article-title 97
###begin article-title 98
Administration of a CO-releasing molecule induces late preconditioning against myocardial infarction.
###end article-title 98
###begin article-title 99
Bilirubin is an antioxidant of possible physiological importance.
###end article-title 99
###begin article-title 100
###xml 62 66 <span type="species:ncbi:10116">rats</span>
Bilirubin ameliorates bleomycin-induced pulmonary fibrosis in rats.
###end article-title 100
###begin article-title 101
Biliverdin protects against polymicrobial sepsis by modulating inflammatory mediators.
###end article-title 101
###begin article-title 102
Biliverdin administration prevents the formation of intimal hyperplasia induced by vascular injury.
###end article-title 102
###begin article-title 103
Biliverdin, a natural product of heme catabolism, induces tolerance to cardiac allografts.
###end article-title 103
###begin article-title 104
Bilirubin: a natural inhibitor of vascular smooth muscle cell proliferation.
###end article-title 104
###begin article-title 105
###xml 82 86 <span type="species:ncbi:10116">rats</span>
Biliverdin administration protects against endotoxin-induced acute lung injury in rats.
###end article-title 105
###begin article-title 106
Heme oxygenase-1-derived bilirubin ameliorates postchemic myocardial dysfunction.
###end article-title 106
###begin article-title 107
Biliverdin reductase: a major physiologic cytoprotectant.
###end article-title 107
###begin article-title 108
Cardioprotective and vasomotor effects of HO activity during acute and chronic hypoxia.
###end article-title 108
###begin article-title 109
Right-ventricular failure is associated with increased mitochondrial complex II activity and production of reactive oxygen species.
###end article-title 109
###begin article-title 110
Heme-oxygenase-1-induced protection against hypoxia/reoxygenation is dependent on biliverdin reductase and its interaction with PI3K/Akt pathway.
###end article-title 110
###begin article-title 111
###xml 93 97 <span type="species:ncbi:10116">rats</span>
Continuous inhalation of carbon monoxide induces right ventricle ischemia and dysfunction in rats with hypoxic pulmonary hypertension.
###end article-title 111
###begin article-title 112
Continuous inhalation of carbon monoxide attenuates hypoxic pulmonary hypertension development presumably through activation of BKCa channels.
###end article-title 112
###begin article-title 113
Caveolin-1 expression by means of p38beta mitogen-activated protein kinase mediates the antiproliferative effect of carbon monoxide.
###end article-title 113
###begin article-title 114
Modulatory role of ERK MAPK-caldesmon pathway in PDGF-stimulated migration of cultured pulmonary artery SMCs.
###end article-title 114
###begin article-title 115
Cardioprotective actions by a water-soluble carbon monoxide-releasing molecule.
###end article-title 115
###begin article-title 116
###xml 32 35 <span type="species:ncbi:10116">rat</span>
Synthesis of stress proteins in rat cardiac myocytes 2-4 days after imposition of hemodynamic overload.
###end article-title 116
###begin p 117
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 117
###begin p 118
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: Research was suppported by the NICHD-sponsored Pediatric Critical Care Scientist Development Program, and NHLBI K08 HL077344 to Dr. Vitali and NIH RO1 HL055454 and HL085446 to Dr. Kourembanas. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 118

